Quercetin and Mast Cells: What the Evidence Actually Shows

The most recommended supplement in the room

Spend a week in any MCAS, POTS or long COVID community and quercetin will come up. It is cheap, it is available everywhere, it does not need a prescription, and it comes with a genuinely appealing story: a natural compound that stabilizes mast cells the way a prescription drug does.

The interesting thing is that the story is not wrong. Quercetin really does stabilize mast cells in the laboratory, and the data behind that claim is stronger than most supplement claims you will encounter. What is missing is almost everything between the laboratory bench and a person swallowing a capsule.

That gap is worth understanding in detail, because it is the difference between “this might be worth carefully trying with my doctor” and “this is proven to work,” and those two statements lead to very different decisions about money, hope and risk.

These are educational field notes, not medical advice, and nothing here diagnoses or treats anything. Talk to your doctor or pharmacist before starting quercetin or any new supplement, particularly if you take other medications. That is not a formality in this case: there are real interactions, covered below.

What quercetin is

Quercetin is a flavonol, one of a large family of plant pigments called flavonoids. You already eat it. It occurs in food mostly as glycosides, meaning the quercetin molecule has a sugar attached, and the specific sugar turns out to matter a lot for absorption.

Typical Western dietary intake lands in the range of tens of milligrams a day, which is well under a single 500 mg supplement capsule. But dietary quercetin is not directly comparable to capsule quercetin, because of the absorption differences we will get to.

A note specific to this audience: some quercetin-rich foods are awkward for people managing histamine load. If you are following a low-histamine approach, the food-first route to quercetin needs to fit that framework rather than fight it.

The strong part: what quercetin does to mast cells

Here the evidence is real and worth taking seriously.

In a 2012 study published in PLoS One, researchers tested quercetin against cromolyn, a prescription mast cell stabilizer, in human mast cells. Both compounds, at 100 micromolar, inhibited secretion of histamine and prostaglandin D2, and both inhibited histamine, leukotrienes and PGD2 from primary human cord blood derived cultured mast cells. But quercetin was more effective than cromolyn at inhibiting IL-8 and TNF release from mast cells stimulated by substance P.

Two details from that study matter more than the headline:

• Quercetin worked prophylactically. Cromolyn had to be added together with the trigger or it rapidly lost its effect. Quercetin was effective when given in advance. For anyone whose triggers are not predictable, a compound that holds a protective effect is a different proposition from one that must be timed to the exposure.
• It acts upstream of antihistamines. This is the single most useful thing to understand about quercetin’s proposed role. An H1 antihistamine blocks the receptor that histamine binds after it has already been released. A mast cell stabilizer aims to reduce the release itself, along with the other mediators that antihistamines do nothing about: prostaglandins, leukotrienes, and inflammatory cytokines like TNF and IL-8.

The honest part: the concentration gap

Now the problem, and it is a big one.

The mast cell experiments above used quercetin at around 100 micromolar. What can you actually get into your blood? In human pharmacokinetic work, consuming onion powder produced a peak plasma concentration of roughly 273 ng/mL, which works out to somewhere around 0.3 micromolar.

That is a gap of a couple of hundred fold between the concentration that worked in the dish and the concentration a generous dietary dose produces in a person.

It gets more complicated. Free quercetin has never been detected in human plasma. During absorption through the intestinal wall and first pass through the liver, quercetin is intensively conjugated by UDP-glucuronosyltransferases and sulfotransferases. What actually circulates is a mixture of quercetin 3-O-glucuronide, quercetin 3’-O-sulfate and isorhamnetin 3-O-glucuronide. Those conjugates are generally less active than the parent compound.

The counterargument worth knowing

There is a genuine scientific response to this, and it is interesting enough that dismissing quercetin on bioavailability alone would be too quick.

Conjugation is reversible in the right conditions. Beta-glucuronidase activity rises at sites of inflammation, and studies have shown that quercetin 3-O-glucuronide binds to macrophage cell surface proteins and is readily deconjugated back into the active aglycone, with that deconjugation significantly enhanced when the macrophages are inflammatory activated. In other words, the circulating conjugate may act as a delivery form that releases active quercetin preferentially at inflamed tissue.

That is a plausible and rather elegant mechanism. It is also not the same as being demonstrated in people with mast cell disease. File it as a reason the story is not closed, not as evidence that it works.

Does the form change things?

Yes, substantially, and this is where supplement choices actually differ.

What the human trials actually found

Here is the full picture, stated plainly.

There is no randomized controlled trial of quercetin in mast cell activation syndrome. Not a small one, not a flawed one. None.

What exists:

• A randomized, double-blind, placebo-controlled trial of EMIQ in Japanese cedar pollinosis. Twenty participants took two 100 mg capsules daily of EMIQ or placebo for 8 weeks during pollen season. Total ocular score and ocular itching were significantly lower in the EMIQ group. This is the strongest human evidence in the family, and it is 20 people, in seasonal allergic rhinitis, using a specific high-bioavailability form, with the significant benefit confined to eye symptoms.
• Two small open-label pilot trials of quercetin in contact dermatitis and photosensitivity, reported alongside the mast cell work above, which showed decreased symptoms. Open-label with no control group means expectation effects are entirely uncontrolled.
• COVID-era trials, mostly small, mostly of quercetin phytosome, mostly in acute infection rather than long COVID, and generally of modest methodological quality. They do not establish a long COVID indication.

None of this means quercetin does not help anyone. It means the confident claims you will read online are running well ahead of what has been shown, and you should calibrate your expectations and your spending accordingly.

Safety and interactions: the part to actually act on

This is the section worth bringing to an appointment.

At ordinary supplement doses, the safety record is reassuring. A published safety review of quercetin as a dietary supplement found no serious adverse events reported from daily doses up to 1000 mg for up to 12 weeks, and adverse effects across human intervention studies have been rare and mild.

Two caveats sit alongside that. Adequate data for long-term use beyond 12 weeks at doses of 1000 mg or more does not exist, so “no evidence of harm” there means genuinely no evidence rather than evidence of safety. And higher doses have been associated with headaches and tingling in the extremities, with caution advised for anyone with pre-existing kidney disease.

The interactions are the real issue, because they are not exotic.

One more consideration specific to mast cell disease: people with MCAS react to supplements, sometimes to the active compound and often to fillers, flow agents, dyes or capsule materials. A reaction to a quercetin product is not proof that quercetin is the problem. It is a reason to look at the whole formulation, and a reason to start at a low dose.

If you and your clinician decide to try it

Assuming you have had the medication conversation and have a green light, the difference between a useful trial and a wasted three months is entirely in the method.

• Change one thing at a time. The single most common way people waste a supplement trial is starting three things in the same week. If quercetin, a new antihistamine and a diet change all begin on Monday, no outcome tells you anything.
• Start low. Given the reaction sensitivity above, a small starting dose with a slow increase gives you a chance to detect a problem before you have taken a full dose of something that does not suit you.
• Set the window and the endpoint in advance. Decide before you start: how long (6 to 8 weeks is reasonable, matching the trial durations above), and what specific outcome would count as success. Write it down. Deciding afterward what counts as improvement is how everything looks like it worked.
• Get a real baseline first. At least four weeks of tracking before you start, otherwise you have nothing to compare against and you will be measuring against memory, which is heavily biased toward the worst recent day.
• Expect regression to the mean. People start supplements when they feel bad. Fluctuating illness tends to drift back toward average on its own. Anything that begins during a flare will look effective as the flare resolves, whether or not it did anything.

Reading your own trial

Fluctuating conditions swing a lot on their own, which is why small improvements are not interpretable. Compare four or more weeks of baseline against the trial period:

Symptom counts are subjective, which is why it helps to have at least one measure that does not depend on how you felt when you filled in the log. Morning HRV and resting heart rate, taken the same way each day, give you an objective line to lay alongside the symptom diary. Neither will move dramatically for a supplement, and you should be suspicious of any claim that they should, but a genuine reduction in inflammatory burden over months tends to show up in the trend rather than in any single reading. The same trigger-tracking discipline that identifies food and environmental triggers is what makes a supplement trial readable.

Frequently asked questions

Does quercetin actually stabilize mast cells? In the laboratory, clearly yes: it inhibits histamine, PGD2 and leukotriene release from human mast cells and blocks IL-8 and TNF more effectively than cromolyn, while also working prophylactically. Whether that holds at the concentrations an oral dose achieves is unresolved, since those studies used about 100 micromolar and realistic plasma levels are a fraction of one micromolar.

Is there real evidence it helps MCAS? There is no randomized controlled trial of quercetin in MCAS. The best human evidence is a 20-person randomized placebo-controlled trial of EMIQ in cedar pollen allergy showing reduced ocular symptoms, plus two uncontrolled open-label pilots in skin conditions.

What form should I take? Plain aglycone is cheapest and among the worst absorbed (~24%), onion glucosides absorb best among food forms (~52%), and enhanced formulations such as lecithin phytosome show roughly 20-fold higher bioavailability than aglycone in pharmacokinetic studies. Because dose equivalence between forms is not straightforward, this is a question for a pharmacist.

What interacts with quercetin? It inhibits CYP3A4 and CYP2C9 and affects P-glycoprotein, so statins, some antidepressants, warfarin and other anticoagulants, cyclosporine, some chemotherapy agents and fluoroquinolone antibiotics are all relevant. Caution with kidney disease. Get a pharmacist to review your list.

How much is in food? Capers are highest (up to ~520 mg per 100 g canned) but are eaten in tiny amounts. Onions are the practical source and their glucoside form absorbs best. Typical dietary intake is tens of milligrams daily.

The bottom line

Quercetin sits in an unusual position: a supplement with a better mechanistic case than most prescription-adjacent compounds and thinner clinical evidence than almost any of them. In a dish, it does what a mast cell stabilizer should do, and does some of it better than the prescription comparator. In a person, the concentration it reaches is orders of magnitude lower, it circulates in conjugated forms, and no one has run the trial that would settle whether it helps MCAS.

That combination justifies careful interest rather than either enthusiasm or dismissal. If you want to try it, the useful version is a real trial: one variable, a low starting dose, a baseline you measured rather than remembered, a fixed window, and an endpoint you defined in advance. And before any of that, a conversation with your doctor or pharmacist about your other medications, because the interaction profile is the part of this article most likely to actually affect you.

Sources and further reading

• Weng Z, Zhang B, Asadi S, Sismanopoulos N, Butcher A, Fu X, Katsarou-Katsari A, Antoniou C, Theoharides TC. Quercetin Is More Effective than Cromolyn in Blocking Human Mast Cell Cytokine Release and Inhibits Contact Dermatitis and Photosensitivity in Humans. PLoS One, 2012.
• Hirano T et al. Effect of Enzymatically Modified Isoquercitrin, a Flavonoid, on Symptoms of Japanese Cedar Pollinosis: A Randomized Double-Blind Placebo-Controlled Trial. International Archives of Allergy and Immunology, 2009.
• Andres S et al. Safety Aspects of the Use of Quercetin as a Dietary Supplement. Molecular Nutrition & Food Research, 2018.
• Lee J, Mitchell AE. Pharmacokinetics of Quercetin Absorption from Apples and Onions in Healthy Humans. J Agric Food Chem, 2012.
• Improving quercetin bioavailability: A systematic review and meta-analysis of human intervention studies. Food Chemistry, 2025.
• Kawai Y et al. Conjugated quercetin glucuronides as bioactive metabolites and precursors of aglycone in vivo. Food & Function, 2011.
• Kawai Y et al. Mitochondrial Dysfunction Leads to Deconjugation of Quercetin Glucuronides in Inflammatory Macrophages. PLoS One, 2013.
• Bandyopadhyay S et al. Inhibitory Effects of Quercetin and Its Main Methyl, Sulfate, and Glucuronic Acid Conjugates on Cytochrome P450 Enzymes, and on OATP, BCRP and MRP2 Transporters. Nutrients, 2020.
• USDA Database for the Flavonoid Content of Selected Foods, Release 3.3. USDA Agricultural Research Service, 2018.